Global Finance News
26 Jun 2026, 15:30
Johnson & Johnson (NYSE: JNJ) gained 3.5% on Friday after receiving fresh analyst support, helping extend the stock's recent strength.
Johnson Rice initiated coverage with a $270 price target, while Guggenheim raised its price target to $270 from $266 and maintained its Buy rating. The updated analyst views reflect confidence in the company's diversified healthcare business, resilient pharmaceutical portfolio, and improving growth outlook.
Analysts continue to view Johnson & Johnson as well positioned to benefit from steady demand for its innovative medicines, expanding medtech business, and strong cash generation. The company is also expected to maintain its defensive appeal amid ongoing macroeconomic uncertainty.
The positive analyst actions reinforced investor sentiment, supporting gains in Johnson & Johnson shares as healthcare stocks attracted renewed interest.
Johnson Rice initiated coverage with a $270 price target, while Guggenheim raised its price target to $270 from $266 and maintained its Buy rating. The updated analyst views reflect confidence in the company's diversified healthcare business, resilient pharmaceutical portfolio, and improving growth outlook.
Analysts continue to view Johnson & Johnson as well positioned to benefit from steady demand for its innovative medicines, expanding medtech business, and strong cash generation. The company is also expected to maintain its defensive appeal amid ongoing macroeconomic uncertainty.
The positive analyst actions reinforced investor sentiment, supporting gains in Johnson & Johnson shares as healthcare stocks attracted renewed interest.